CE Mark For Medtronic’s Engager Transcatheter Valve, Based On Positive Clinical Study Outcomes

Medtronics Engager Transapical ValveIn short

Medtronic, Inc. has gained CE mark approval for its Engager Transcatheter Aortic Valve Implantation (TAVI) System. Engager is designed for transapical delivery to treat patients with severe aortic stenosis who are at high or extreme risk for surgical aortic valve replacement (SAVR).

Background

The Engager valve uses a minimally‐invasive delivery system via a catheter inserted in the apex of the heart. The valve is comprised of bovine tissue leaflets and a self‐expanding nitinol frame designed to promote annular sealing to minimize paravalvular leak. Control arms simplify implantation, and the supra-annular valve positioning facilitates so-called leaflet coaptation in non-circular anatomy for optimal hemodynamic performance. Medtronic says a direct aortic delivery system for Engager will be introduced in the future.

The approval comes on the back of a European Pivotal Multi-center Trial which demonstrated positive clinical outcomes. Results were presented during late-breaking trial sessions at the recent European Association for Cardio-Thoracic Surgery (EACTS) and the Society of Thoracic Surgeons (STS) annual meetings.

Considering the complexity and well-established learning curve when implanting valves using the transapical approach, the Engager study revealed high rates of procedural success, minimal paravalvular leak (PVL) and continuing clinical benefits for patients over time. Transapical delivery as used in the trial resulted in 94.3 percent overall device success (according to Valve Academic Research Consortium modified definitions). There were no procedures requiring a second valve and no occurrences of valve embolisation, coronary obstruction or device malposition. No patients had moderate or severe PVL at six months, as measured by an independent echocardiography core lab. In addition, while most patients (88 percent) were NYHA Class III or IV at baseline, at six months 82 percent of patients had improved to NYHA Class I or II.

Company comments

“The Engager valve has demonstrated exceptional clinical results, and by adding it to our transcatheter valve portfolio, we are providing heart teams with more options for achieving the best outcomes for every patient with severe aortic stenosis,” said John Liddicoat, M.D., senior vice president of Medtronic and president of the Medtronic Structural Heart Business.

Source: Medtronic, Inc.